1. A method of scheduling an output in a crosspoint buffered switch, the method comprising:
searching whether a cell exists in a crosspoint buffer at a start position for each output port, wherein the crosspoint buffer at the start position is a crosspoint buffer at a predetermined position among the crosspoint buffers respectively corresponding to output ports;
outputting all cells stored in the crosspoint buffer at the start position and searching for a cell in a crosspoint buffer at a next position;
outputting all cells stored in the crosspoint buffer at the next position and searching for a cell in the crosspoint buffer in a next position to the crosspoint buffer at the final position; and
outputting all cells stored in the crosspoint buffer at the final position and searching for a cell in the crosspoint buffer at the start position.
2. The method as claimed in claim 1, prior to the searching of a cell in a crosspoint buffer at a start position, further comprising storing cells received through a predetermined input port in the crosspoint buffers assigned for each of the input ports and output ports by the crosspoint buffered switch.
3. The method as claimed in claim 2, wherein the storing of cells received through a predetermined input port further comprises storing the cells at corresponding positions of a N\xd7M number of crosspoint buffers corresponding to an N number of the input ports and an M number of the output ports.
4. The method as claimed in claim 2, wherein the number of the crosspoint buffers corresponding to the respective output ports are the same as the number of the input ports and each of the crosspoint buffers is assigned for each input port.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical composition for photochemotherapeutically treating an auto-immune disease, characterized in that said composition contains as an active ingredient mono-L-aspartyl chlorin e6 or mono-L-glutamyl chlorin e6 or a pharmacologically acceptable salt thereof.
2. A composition as claimed in claim 1, wherein the compound used as the active ingredient is mono-L-aspartyl chlorin e6 or its tetra-sodium salt.
3. A composition as claimed in claim 1, wherein the compound used as the active ingredient is mono-L-glutamyl chlorin e6 or its tetra-sodium salt.
4. A method for photochemotherapeutically treating an auto-immune disease, which comprises administering orally or parenterally to a patient having an auto-immune disease to be treated a therapeutically effective amount of mono-L-aspartyl chlorin e6 or mono-L-glutamyl chlorin e6 or a pharmacologically acceptable salt thereof, irradiating the blood stream present in the blood vessel and containing the administered compound with an ultraviolet ray or a laser light, thereby to subject the mono-L-aspartyl chlorin e6 or mono-L-glutamyl chlorin e6 or salt thereof contained in said blood stream to exposure with the irradiating ultraviolet ray or laser light and to excite said compound photochemically, and effecting the administration of the mono-L-aspartyl chlorin e6 or mono-L-glutamyl chlorin e6 or salt thereof only once or two times or more and also repeating once more, twice or more times more the irradiation of the ultraviolet ray or laser light for the photochemical excitation of said compound contained in the blood stream, until the antibody value of the auto-antibody which is present in the blood of the patient and is specific to the auto-immune disease to be treated has been decreased significantly.
5. A method as claimed in claim 4, wherein the compound administered is mono-L-aspartyl chlorin e6 or its tetra-sodium salt.
6. A method as claimed in claim 4, wherein the compound administered is mono-L-glutamyl chlorin e6 or its tetra-sodium salt.
7. A method as claimed in claim 4, wherein the laser light irradiated is laser light having a wavelength in the range of 620 to 760 nm.
8. A method as claimed in claim 4, wherein the autoimmune disease to be treated is systemic lupus erythematosus.
9. Use of mono-L-aspartyl chlorin e6 or mono-L-glutamyl chlorin e6 or a pharmacologically acceptable salt thereof, in the preparation of a pharmaceutical composition for treating an auto-immune disease photochemotherapeutically.
10. A process for the preparation of a pharmaceutical composition for treating an auto-immune disease photochemotherapeutically, which comprises admixing mono-L-aspartyl chlorin e6 or mono-L-glutamyl chlorin e6 or a pharmacologically accept able salt thereof with a pharmaceutically acceptable carrier or carriers.